HIV care should be delivered by a multidisciplinary team (MDT), the precise composition of which will vary. Grading: 1D 1 Proportion of pregnant women newly diagnosed with HIV having a sexual health screen. 2 Proportion of newly diagnosed women, requiring cART for their own health, starting treatment within 2 weeks of diagnosis. 3 Proportion of women who have commenced ART by beginning of week 24 of pregnancy. 4 Proportion of women with a baseline HIV viral load > 30 000 RNA copies/mL plasma and who do not require treatment for themselves commencing temporary cART at the beginning of the second trimester (by beginning of 16 weeks’ gestation). 5 Proportion of women presenting in labour/with ROM/requiring delivery Ruxolitinib without a documented HIV result having an urgent HIV test result documented and this reactive/positive result acted upon immediately with initiation of the interventions to PMTCT without waiting for further/formal serological confirmation. 6 Proportion of women with hepatitis B virus co-infection who have liver function tests performed 2 weeks after commencing cART to detect evidence of antiretroviral hepatotoxicity
p38 MAPK inhibitor or IRIS. 7 Proportion of women with hepatitis C virus co-infection who have liver function tests performed 2 weeks after commencing cART to detect evidence of antiretroviral hepatotoxicity or IRIS. 8 Proportion of women who have invasive prenatal diagnostic testing performed before their HIV status is known. 9 Proportion of emergency
Caesarean sections performed and their indication. 10 Proportion of infants < 72 hours old, born to untreated HIV-positive mothers, initiating three-drug therapy within 2 hours of delivery. 11 Proportion of routine neonatal PEP commenced within 4 hours of delivery. 12 Benzatropine Proportion of infants born to HIV-positive mothers who have HIV antibody testing for seroreversion performed at age 15–24 months. One of the major successes in the management of HIV-positive patients has been the prevention of mother-to-child transmission (MTCT) of HIV-1. With the widespread implementation of routine antenatal screening for HIV-1, transmission of HIV-1 from mother to child is now a rare occurrence in the UK. Despite few recent randomized controlled trials regarding the use of antiretroviral therapy (ART) in pregnancy or obstetric intervention, practice continues to evolve. This is largely informed by observational data, theoretical considerations and expert opinion.